AZN Stock Analysis: Buy, Sell, or Hold?
AZN - AstraZeneca PLC
$201.46
0.73 (0.36%)
▲
5d:
+9.85%
30d:
-0.03%
90d:
+119.15%
HOLD
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 05, 2026
Get Alerted When AZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AZN trades at premium valuation expecting 4.8% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: AZN trades at premium valuation expecting 4.8% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$235.74
Based on 9.7% avg growth
INTRINSIC VALUE TODAY
$146.38
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AZN is currently trading at $201.46, which is considered slightly high relative to its 30-day fair value range of $187.56 to $202.37. From a valuation perspective, the stock is trading at a premium (Forward PE: 33.6) compared to its historical average (29.2). At these levels, the market is pricing in 4.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AZN is in a strong uptrend. The price is approaching resistance at $200.81. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AZN is in a strong uptrend. The price is approaching resistance at $200.81. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$187.56 -
$202.37
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
59.5%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($208.77)
- NEUTRAL: Trading at premium valuation - market expects 4.8% growth which is achievable
Fair Price Analysis
30-Day Fair Range
$187.56 -
$202.37
Current vs Fair Value
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$182.39
Resistance Level
$200.81
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
33.63
Wall Street Target
$208.77
(+4.0%)
Revenue Growth (YoY)
4.1%
Earnings Growth (YoY)
53.9%
Profit Margin
17.4%
Valuation Premium vs History
+4.8% premium
PE vs Historical
33.6 vs 29.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.8%
(market-implied from PE analysis)
1-Year Target
$210.37
(+5%)
2-Year Target
$220.46
(+10%)
3-Year Target
$231.04
(+15%)
3-Yr Target (if PE normalizes)
(PE: 34→29)
PE COMPRESSION
$200.61
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 33.6, Growth: 15.3%)
$307.35
(+53%)
Base:
(SPY PE: 22.4, Growth: 15.3%)
$204.26
(+2%)
Bear:
(PE: 19.0, Growth: 15.3%)
$173.62
(-14%)
📈
Valuation based on Current Earnings
Trailing PE: 28.07 | Current EPS (TTM): $6.54
Bull Case
$184.32
(+0%)
Analyst growth -8.7%, PE expands to 30.9
Base Case
$167.57
(-9%)
Market implied -8.7%, PE stable at 28.1
Bear Case
$124.85
(-32%)
Severe decline -20.0%, PE contracts to 23.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: April 02, 2026 10:36 AM ET
Data refreshes hourly during market hours. Next update: 11:36 AM
Data refreshes hourly during market hours. Next update: 11:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AZN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1209 | 58 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 54 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$249 | 64 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$351 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$206 | 57 HOLD |
